Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Tax Provisions (2022 - 2025)

Historic Tax Provisions for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $166000.0.

  • Centessa Pharmaceuticals' Tax Provisions fell 7269.74% to $166000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 1541.87%. This contributed to the annual value of $2.8 million for FY2024, which is 11135.06% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Tax Provisions of $166000.0 as of Q3 2025, which was down 7269.74% from $778000.0 recorded in Q2 2025.
  • Centessa Pharmaceuticals' Tax Provisions' 5-year high stood at $1.4 million during Q1 2025, with a 5-year trough of -$24.1 million in Q2 2023.
  • Over the past 4 years, Centessa Pharmaceuticals' median Tax Provisions value was $481000.0 (recorded in 2024), while the average stood at -$1.4 million.
  • Examining YoY changes over the last 5 years, Centessa Pharmaceuticals' Tax Provisions showed a top increase of 74625.0% in 2023 and a maximum decrease of 10922272.73% in 2023.
  • Over the past 4 years, Centessa Pharmaceuticals' Tax Provisions (Quarter) stood at -$664000.0 in 2022, then surged by 272.29% to $1.1 million in 2023, then decreased by 8.22% to $1.0 million in 2024, then tumbled by 84.19% to $166000.0 in 2025.
  • Its Tax Provisions stands at $166000.0 for Q3 2025, versus $778000.0 for Q2 2025 and $1.4 million for Q1 2025.